Overview

SFX-01 After Subarachnoid Haemorrhage

Status:
Completed

Trial end date:
2019-11-01

Target enrollment:

Participant gender:

Summary

This is a Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SFX-01 in Subarachnoid Haemorrhage, with exploratory evaluations of efficacy.

Phase:

Phase 2

Details

Lead Sponsor:

Evgen Pharma